News

  • Swissmedic approves Intrarosa® (prasterone) for the treatment of vulvovaginal atrophy in postmenopausal women

    3 June 2020

    Swissmedic approves Intrarosa® (prasterone) for the treatment of vulvovaginal atrophy in postmenopausal women A novel drug for the treatment of vulvovaginal atrophy based on prasterone (DHEA)   Geneva, the 02.06.2020 – On 19.05.2020, Swissmedic, the Swiss Agency for Therapeutic Products, granted a marketing authorization for the active substance prasterone for the local treatment of vulvovaginal […]

  • COVID-19: Labatec update

    5 May 2020

    In line with our historic commitment to our healthcare partners, Labatec is continuing to multiply its efforts to help our customers and patients navigate the challenges of the COVID-19 pandemic. Now more than ever, we are taking action to ensure that our supply of essential medicines particularly used to treat COVID-19 patients remains uninterrupted despite […]

  • Labatec signs an LSA with Mithra for a contraceptive ring in Switzerland

    5 May 2020

      Mithra grants license to Labatec for commercialization of vaginal contraceptive ring in Switzerland Production of Myring™ at the Mithra CDMO facility in Belgium Agreement follows licensing deals with major international market leaders forcommercialization of Myring™ Liege, Belgium, 05 December 2019 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s […]


Medical Congresses & Conferences

Partnering & Corporate Development Events

Get in touch

Would you like to discuss a collaboration or partnership project? Get in touch with us at partnering@labatec.ch or connect with us at one of the upcoming events.

For other enquiries, please visit our contact page.